SCHEME 1. Synthetic Approaches for Benzofuro
Heterocycles 5
Facile Assembly of Fused Benzo[4,5]furo
Heterocycles
Jing Liu,* Anne E. Fitzgerald, and Neelakandha S. Mani
Johnson & Johnson Pharmaceutical Research & DeVelopment,
L.L.C., 3210 Merryfield Row, San Diego, California 92121
ReceiVed January 10, 2008
first, followed by the construction of the heterocyclic ring5
(Scheme 1). This approach usually requires lengthy multistep
synthesis. Alternatively, the retrosynthetic disconnection can be
made at the C3-C4 bond of the central furan ring. This bond
is often formed by the reductive dehalocoupling of diaryl ether
7a,6 dehydrohalogenation of 7b,7 or oxidative coupling of 7c.8
Finally, a more classical but less utilized route involves the
intramolecular cyclization of biaryl phenol 8.9 This approach
offers distinctly different synthetic opportunities but is often
avoided owing to the harsh conditions usually required for the
intramolecular cyclization and the lack of a general method for
the preparation of biaryl phenol 8.
In our lead optimization studies, benzofuropyrimidine 9 was
identified as a key intermediate. Initially, 9 was prepared from
2-cyanophenol 10 via a multistep sequence, in which the furan
and pyrimidine rings were constructed sequentially (Scheme 2a).
We envisioned that 9 might be synthesized via a more concise
route (Scheme 2b). A regioselective Suzuki coupling between
boronic acid 11 and 2,4,5,6-tetrachloropyrimidine (12) could
A concise synthesis of fused benzo[4,5]furo heterocycles 18
has been developed. Chemo/regioselective Suzuki coupling
between 1,2-dihaloarene 17 and R-hydroxyphenylboronic
acid or ester 20 gives biaryl phenol 19, which then undergoes
copper(I) thiophene-2-carboxylate (CuTC)-mediated intramo-
lecular cyclization to afford 18 in good overall yield. This
method has broad substrate scope and allows facile assembly
of a wide variety of benzo[4,5]furo heterocycles.
Fused benzofuro heterocycles are common structural motifs
in biologically active compounds and drug candidates (Figure
1). For example, Elbfluorene (1) and its derivatives are
interesting leads as cyclin-dependent kinase (CDK) inhibitors.1
Benzofurocoumarins such as 2 were found to inhibit the growth
of several human cancer cell lines.2 Benzofuropyrimidine 3 (MP-
470, SuperGen Inc.)3 is a novel multitarget tyrosine kinase
inhibitor currently in Phase I clinical trials, while compound 4
and its analogues were found to be histamine H4 modulators.4
(5) (a) Dixit, M.; Raghunandan, R.; Kumar, B.; Maulik, P. R.; Goel, A.
Tetrahedron 2007, 63, 1610-1616. (b) Liebeskind, L. S.; Wang, J. J. Org.
Chem. 1993, 58, 3550-3556. (c) Ando, Y.; Ando, K.; Yamaguchi, M.;
Kunitomo, J.; Koida, M.; Fukuyama, R.; Nakamuta, H.; Yamashita, M.;
Ohta, S.; Ohishi, Y. Bioorg. Med. Chem. Lett. 2006, 16, 5849-5854. (d)
Gerster, M.; Wicki, R. Synthesis 2004, 249-254. (e) Isomura, K.; Noguchi,
S.; Saruwatari, M.; Hatano, S.; Taniguchi, H. Tetrahedron Lett. 1980, 21,
3879-3882. (f) Degl’Innocenti, A.; Funicello, M.; Scafato, P.; Spagnolo,
P. Tetrahedron Lett. 1997, 38, 2171-2174. (g) Gonza´lez-Go´mez, J. C.;
Uriarte, E. Synlett 2002, 2095-2097. (h) Shafiee, A.; Behnam, E. J.
Heterocycl. Chem. 1978, 15, 1459-1462. (i) Yamaguchi, S.; Tsuzuki, K.;
Sannomiya, Y.; Oh-hira, Y.; Kawase, Y. J. Heterocycl. Chem. 1989, 26,
285-287. (j) Sargent, M. V.; Stransky, P. O. J. Chem. Soc., Perkin Trans.
1 1982, 1605-1610.
(6) Sanz, R.; Ferna´ndez, Y.; Castroviejo, M. P.; Pe´rez, A.; Fan˜ana´s, F.
J. J. Org. Chem. 2006, 71, 6291-6294.
(7) (a) Liu, Z.; Larock, R. C. Tetrahedron 2007, 63, 347-355. (b) Zhang,
Y.-M.; Razler, T.; Jackson, P. F. Tetrahedron Lett. 2002, 43, 8235-8239.
(c) Ames, D. E.; Opalko, A. Synthesis 1983, 234-235.
(8) (a) Åkermark, B.; Eberson, L.; Jonsson, E.; Pettersson, E. J. Org.
Chem. 1975, 40, 1365-1367. (b) De Lombaert, S.; Blanchard, L.; Stamford,
L. B.; Tan, J.; Wallace, E. M.; Satoh, Y.; Fitt, J.; Hoyer, D.; Simonsbergen,
D.; Moliterni, J.; Marcopoulos, N.; Savage, P.; Chou, M.; Trapani, A. J.;
Jeng, A. Y. J. Med. Chem. 2000, 43, 488-504. (c) Zeller, K.-P.; Petersen,
H. Synthesis 1975, 532-533. Also see ref 5j.
FIGURE 1. Biologically active benzo[4,5]furo heterocycles.
Numerous syntheses of benzo[4,5]furo heterocycle 5 have
been reported. Most often, a benzofuran derivative 6 is prepared
(9) For the synthesis of dibenzofurans via this approach, see: (a)
Kawaguchi, K.; Nakano, K.; Nozaki, K. J. Org. Chem. 2007, 72, 5119-
5128. (b) Mart´ınez, A.; Ferna´ndez, M.; Este´vez, J. C.; Este´vez, R. J.;
Castedo, L. Tetrahedron 2005, 61, 1353-1362. (c) Litinas, K. E.;
Nicolaides, D. N. J. Chem. Soc., Perkin Trans. 1 1985, 429-435. For
benzofuropyridines, see: (d) Yue, W. S.; Li, J. J. Org. Lett. 2002, 4, 2201-
2203. (e) Abramovitch, R. A.; Inbasekaran, M. N.; Kato, S.; Radzikowska,
T. A.; Tomasik, P. J. Org. Chem. 1983, 48, 690-695. (f) Parmentier, M.;
Gros, P.; Fort, Y. Tetrahedron 2005, 61, 3261-3269. For benzofuropyra-
zines, see: (g) Coates, W. J.; McKillop, A. J. Org. Chem. 1990, 55, 5418-
5420.
(1) Voigt, B.; Meijer, L.; Lozach, O.; Scha¨chtele, C.; Totzke, F.;
Hilgeroth, A. Bioorg. Med. Chem. Lett. 2005, 15, 823-825.
(2) Oliveira, A. M. A. G.; Raposo, M. M. M.; Oliveira-Campos, A. M.
F.; Machado, A. E. H.; Puapairoj, P.; Pedro, M.; Nascimento, M. S. J.;
Portela, C.; Afonso, C.; Pinto, M. Eur. J. Med. Chem. 2006, 41, 367-372.
(3) Hurley, L. H.; Mahadevan, D.; Han, H.; Bearss, D. J.; Vankayalapati,
H.; Bashyam, S.; Munoz, R. M.; Warner, S. L.; Della, C. K.; Von Hoff, D.
D.; Grand, C. L. PCT Int. Appl. WO 2005/037825, 2005.
(4) Harris, N.; Higgs, C.; Wren, S.; Dyke, H. J.; Price, S.; Cramp, S.
PCT Int. Appl. WO 2006/050965, 2006.
10.1021/jo8000595 CCC: $40.75 © 2008 American Chemical Society
Published on Web 03/11/2008
J. Org. Chem. 2008, 73, 2951-2954
2951